healthcare data - search results

Researchers from the Universitat Autònoma de Barcelona (UAB) have played a key role in developing a revolutionary switch capable of operating at unprecedented frequencies with minimal power consumption Traditional silicon-based switches, ubiquitous in current telecommunications devices, have limitations in speed and energy efficiency. These devices require a constant power supply to...

Despite affecting a significant portion of the population, the impact of rheumatic and musculoskeletal diseases (RMDs) is often underestimated, with many people living with RMDs, and their families, in need of greater care and support. Lynne Woolley at Versus Arthritis spoke to Lorna Rothery about the physical and psychological challenges of RMDs and what can be done.

Suzanne Wait and Catherine Whicher, from The Health Policy Partnership, suggest that digital health should prioritise the inclusion of women at its core.

Sabih Chaudhry, CEO of Afon Technology Ltd, describes the company’s innovative Glucowear™ — the world’s first non-invasive, real-time, and continuous blood glucose sensor.

Rishi Sunak has announced his resignation as leader of the Conservative Party following what can be described as a catastrophic night for his party.

Nick Denning, CEO of IT consultancy Diegesis, and veteran of multiple successful digital transformation projects, shares insights on protecting your organisation and identifying security vulnerabilities in the face of increasing cyberattacks.

Professor Suzanne Verstappen discusses the impact and challenges associated with juvenile-onset rheumatic and musculoskeletal diseases when navigating education and employment.

Thomas J. Webster, PhD provides a firsthand account of the obstacles hindering innovation in medicine, covering publishing, conferences, politics, funding, universities, and industry.

In a move to improve care for individuals with Attention Deficit Hyperactivity Disorder (ADHD), NHS England has announced the formation of a new task force in collaboration with the government.

As the UK gears up for the upcoming election on July 4th, new polling data from Ipsos reveals distinct contrasts in voter priorities between the main political parties.

The Pain PLUS literature surveillance service demonstrates the importance of high-quality literature to support decision-making and practice for the use of opioids.

AI model named Candycrunch has been designed to transform cancer detection through advanced sugar analysis.

BreastScreen Norway discusses how the results from their screening programme for early breast cancer detection can influence future artificial intelligence to streamline early breast cancer detection.

Neurological diseases are the foremost cause of ill health and disability worldwide. Open Access Government offers an overview of the prevalence of these conditions.

In this Q&A, a team from the RESTART project explores their groundbreaking intervention model designed to empower people to embrace healthier lifestyles as they near retirement.

The health and social care sectors in the UK are facing significant challenges in 2024. Ongoing backlogs, skilled workforce shortages, and increasing service demand are creating a perfect storm - but what can be done to change this?

Priya Hays, M.S., Ph.D. is an accomplished science writer Hays has written and published five books as well as having authored over twenty publications in journals as varied as the Bulletin of Science, Technology and Society, L’Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, Journal of Clinical Investigation and Studies,...

What impact does machine learning have on clinical care? A study reveals that AI-generated alerts can significantly enhance patient outcomes.

Jie Gu, Associate Professor from Northwestern University, examines AI-empowered neural processing for intelligent human-machine interface and biomedical devices.

An optimal drug for chronic neurological disease would slow down disease progression in the long term, with short-term symptomatic benefits. This would shorten clinical development timelines and reduce the cost and risk level for drug developers. Henri Huttunen Chief Scientific Officer (CSO) at Herantis Pharma Plc explains.